drug
(drospirenone + estetrol)
Marketedupdated 4mo agoby Mayne Pharma USA Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 15, 2028
~1.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Oct 1, 2043method-of-use (U-3152)US 12458649
- Feb 9, 2043formulationUS 12233074
- Jun 17, 2036formulationUS 11793760
- Jun 17, 2036formulationUS 11957694
- Jun 17, 2036formulationUS 11964055
- Jun 17, 2036formulationUS 12427114
- Jan 15, 2028formulationUS 77324301.4y
FDA exclusivities (1)
- Apr 15, 2026NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that